Press Releases | Gilead - Gilead Sciences
WEBJul 25, 2024 · Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024. January 22, 2024. Gilead Provides Update on Phase 3 EVOKE-01 Study. Read the latest news about Gilead's work in COVID-19, HIV, viral hepatitis, cancer and other areas.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% ... - Gilead Sciences
WEBJun 20, 2024 · The results demonstrated superiority of twice-yearly lenacapavir over bHIV (primary endpoint, incidence 2.41 per 100 person-years) and superiority of twice-yearly lenacapavir over once-daily Truvada (secondary endpoint), with p<0.0001 for …
Newsroom | Gilead - Gilead Sciences
WEBRecent Press Releases. September 12, 2024. Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial. September 10, 2024. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBFOSTER CITY, Calif., June 20, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial...
Gilead Sciences Expands Liver Portfolio With Acquisition of …
WEBFeb 12, 2024 · FOSTER CITY, Calif. & NEWARK, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
Gilead Sciences to Acquire MiroBio
WEBAug 4, 2022 · MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week.
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
WEBFeb 6, 2024 · Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.1 billion in the fourth quarter 2023 compared to the same period in 2022, primarily reflecting higher demand, partially offset by lower average realized price due to channel mix.
Gilead PrEP lenacapavir succeeds in Phase 3 trial - CNBC
WEBJun 20, 2024 · Key Points. Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the lenacapavir shot contracted HIV. Gilead needs ...
Gilead Sciences Announces Fourth Quarter and Full Year 2022 …
WEBFeb 2, 2023 · Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results. Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022. Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022. Oncology Sales Increased Year-Over-Year by 71% for Full Year 2022.
Gilead Sciences Announces Second Quarter 2022 Financial Results
WEBTotal second quarter 2022 revenue increased 1% to $6.3 billion compared to the same period in 2021, primarily due to increased sales in HIV and oncology products, offset partially by decreased sales of Veklury® (remdesivir) and hepatitis C …
Skip to content